Aerpio's Tie2 activator fails diabetic retinopathy trial

Aerpio said twice-daily 15 mg subcutaneous AKB-9778 missed the primary endpoint in the Phase

Read the full 146 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE